TCR2 Therapeutics (TCR2 Therapeutics) Debt-to-Equity : 0.06 (As of Mar. 2023)

View and export this data going back to 2019. Start your Free Trial

What is TCR2 Therapeutics Debt-to-Equity?

TCR2 Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $3.27 Mil. TCR2 Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $2.71 Mil. TCR2 Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2023 was $101.33 Mil. TCR2 Therapeutics's debt to equity for the quarter that ended in Mar. 2023 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for TCR2 Therapeutics's Debt-to-Equity or its related term are showing as below:

TCRR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06 Med: 0.11 Max: 0.29
Current: 0.06

During the past 7 years, the highest Debt-to-Equity Ratio of TCR2 Therapeutics was 0.29. The lowest was 0.06. And the median was 0.11.

TCRR's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs TCRR: 0.06

TCR2 Therapeutics Debt-to-Equity Historical Data

The historical data trend for TCR2 Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TCR2 Therapeutics Debt-to-Equity Chart

TCR2 Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.09

0.18

TCR2 Therapeutics Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Debt-to-Equity	Get a 7-Day Free Trial															0.21	0.28	0.29	0.18	0.06

Competitive Comparison of TCR2 Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, TCR2 Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TCR2 Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TCR2 Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where TCR2 Therapeutics's Debt-to-Equity falls into.

TCR2 Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

TCR2 Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(21.834	+	3.316)	/	140.859
	=	0.18

TCR2 Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.268	+	2.71)	/	101.33
	=	0.06

TCR2 Therapeutics (NAS:TCRR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

TCR2 Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of TCR2 Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

TCR2 Therapeutics (TCR2 Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TCR2 Therapeutics Inc (NAS:TCRR) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Binney Street, Suite 710, Cambridge, MA, USA, 02142

Website

https://www.tcr2.com

TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its proprietary, first-in-class TCR Fusion Construct T cells (TRuC-T cells). The company's TRuC-T cells specifically recognize and kill cancer cells by harnessing the entire TCR signaling complex, independent of human leukocyte antigens, which are effective in patients with solid tumors.

Executives

Kevin C Tang	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Ansbert Gadicke	director, 10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Mpm Asset Management Llc	10 percent owner	399 BOYLSTON STREET, SUITE 1100, BOSTON MA 02116
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Shawn Tomasello	director	C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Priti Hegde	director	TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142
Rosemary Harrison	officer: Chief Business & Strategy	C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Garry E Menzel	director, officer: President & CEO	C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Peter Olagunju	officer: Chief Technical Officer	TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142
Alfonso Quintas Cardama	officer: Chief Medical Officer	C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Angela Justice	officer: Chief People Officer	310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Eric Sullivan	officer: Chief Financial Officer	GOODWIN PROCTER LLP, 53 STATE ST, BOSTON MA 02109
Mayur Ian Somaiya	officer: Chief Financial Officer	TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Axel Hoos	director	C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142